SV Health Investors, Sanofi Ventures, Abingworth, and SymBiosis led a $112m Series C round in AdvanCell.

SV Health Investors, Sanofi Ventures, Abingworth, and SymBiosis led a $112m Series C round in AdvanCell, a clinical-stage radiopharmaceutical company, with participation from Morningside, Tenmile and Brandon Capital. This investment will fuel AdvanCell’s ongoing efforts to expand its manufacturing capacity, accelerate the clinical development of its pipeline of radionuclide therapies, and advance its mission of delivering life-changing treatments to cancer patients worldwide.